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Abstract: Colorectal cancer (CRC) is the third most common cancer and the fourth most common
cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence
increasing year by year. The probability of suffering from colorectal cancer is about 4%–5% and
the risk for developing CRC is associated with personal features or habits such as age, chronic
disease history and lifestyle. In this context, the gut microbiota has a relevant role, and dysbiosis
situations can induce colonic carcinogenesis through a chronic inflammation mechanism. Some of
the bacteria responsible for this multiphase process include Fusobacterium spp, Bacteroides fragilis
and enteropathogenic Escherichia coli. CRC is caused by mutations that target oncogenes, tumour
suppressor genes and genes related to DNA repair mechanisms. Depending on the origin of the
mutation, colorectal carcinomas can be classified as sporadic (70%); inherited (5%) and familial
(25%). The pathogenic mechanisms leading to this situation can be included in three types, namely
chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype
(CIMP). Within these types of CRC, common mutations, chromosomal changes and translocations
have been reported to affect important pathways (WNT, MAPK/PI3K, TGF-β, TP53), and mutations;
in particular, genes such as c-MYC, KRAS, BRAF, PIK3CA, PTEN, SMAD2 and SMAD4 can be used
as predictive markers for patient outcome. In addition to gene mutations, alterations in ncRNAs,
such as lncRNA or miRNA, can also contribute to different steps of the carcinogenesis process
and have a predictive value when used as biomarkers. In consequence, different panels of genes
and mRNA are being developed to improve prognosis and treatment selection. The choice of
first-line treatment in CRC follows a multimodal approach based on tumour-related characteristics
and usually comprises surgical resection followed by chemotherapy combined with monoclonal
antibodies or proteins against vascular endothelial growth factor (VEGF) and epidermal growth
receptor (EGFR). Besides traditional chemotherapy, alternative therapies (such as agarose tumour
macrobeads, anti-inflammatory drugs, probiotics, and gold-based drugs) are currently being studied
to increase treatment effectiveness and reduce side effects.
Keywords: colorectal carcinoma; ncRNA; microbiota; biomarkers; gene-expression profiling; agarose
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1. Methodology
The present report has adhered to systematic review guidelines. All data were collected according
to the criteria shown in Figure 1. The search of each of the different parts in PubMed (avaliable on:
http://www.ncbi.nlm.nih.gov/pubmed) identified a total of 295 hits from November 1945 to July 2014.
In addition, a search was carried out in the databases Long Noncoding RNA Database v2.0 [1,2] and
miRCancer: a microRNA-cancer association database [3–5] and the results obtained were corroborated
by a literature search in PubMed. The combined information from these two sources formed the basis
of this review.
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2. Introduction
2.1. Epidemiology
Col rectal cancer (CRC) is one of the most common cancers worldwide, with between one
and two milli n new cases being diagnosed very year, thus making CRC t e third most common
cancer and the fourth most co mon cause of cancer-related death, with 700,000 deaths per year,
exceeded only by lung, liver and stomach cancers. By gender, CRC is the second most common
cancer in women (9.2%) and the third in men (10%) [6]. The incidence of CRC has risen by more than
200,000 new cases per year from 1990 to 2012. Most cases of CRC are detected in Western countries
(55%), but this tendency is changing due to the fast development of some countries over the past few
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years [7]. Even so, only 33% of all CRC-related deaths in the world occur in Western countries in
2010 [8] thanks to the improvements made in health systems and the implementation of screening
programs. However, predictions for 2016 are not encouraging at all, with 134,490 new cases of colorectal
cancer and 49,190 deaths related to this cancer expected.
2.2. Aetiology
Mutations in specific genes can lead to the onset of colorectal cancer, as happens in other types
of cancer. Those mutations can appear in oncogenes, tumour suppressor genes and genes related to
DNA repair mechanisms [9]. Depending on the origin of the mutation, colorectal carcinomas can be
classified as sporadic, inherited and familial.
Point mutations, which appear during life, are not associated with inherited syndromes and only
affect individual cells and their descendants. Cancers derived from point mutations are called sporadic
cancers, and account for 70% of all colorectal cancers. The molecular pathogenesis of sporadic cancer is
heterogeneous as mutations can target different genes [9]. However, approximately 70% of CRC cases
follow a specific succession of mutations that is then translated into a specific morphological sequence,
starting with the formation of an adenoma and ending in the carcinoma state. The first mutation
occurs in adenomatous polyposis coli (APC), a tumour suppressor gene, triggering the formation of
non-malignant adenomas, also called polyps. Approximately 15% of those adenomas are expected to
be promoted to the carcinoma state within a period of ten years. This APC mutation is followed by
mutations in KRAS, TP53 and, finally, DCC [9].
Inherited cancers account for just 5% of all CRC cases. Those cancers are caused by inherited
mutations that affect one of the alleles of the mutated gene, meaning that a point mutation in
the other allele will trigger the apparition of the tumour cell and, subsequently, the carcinoma.
In order to generate a more accurate classification of inherited cancers, two groups, namely polyposis
and non-polyposis forms, have been established. The polyposis variant mainly involves familial
adenomatous polyposis (FAP), which is characterized by the formation of multiple potentially
malignant polyps in the colon [10]. In contrast, hereditary non-polyposis colorectal cancer (HNPCC)
is related to mutations in DNA repair mechanisms. The main cause of HNPCC is Lynch syndrome,
which is caused by inherited mutations in one of the alleles coding for DNA repair proteins such as
MSH2, MLH1, MLH6, PMS1 and PMS2. Lynch syndrome can be found in 2%–3% of all colorectal
cancer cases, and is therefore the most common syndrome in the HNPCC group [10,11]. Familial
colorectal cancer accounts for approximately 25% of all cases and is also caused by inherited mutations,
although they are not classified as inherited cancers per se since they cannot be included in any
inherited cancer variant [12].
2.3. Risk Factors
Worldwide, the probability of suffering from colorectal cancer is about 4%–5%. Furthermore,
many personal traits or habits are considered to be risk factors as they increase the chances of
developing polyps or colorectal cancer.
The main risk factor for colorectal cancer is age: past the fifth decade of life, the risk of developing
CRC is markedly increased, while the onset of colorectal cancer below the age of fifty is rare
(apart from inherited cancers) [13]. In addition to age, there are other inherent risk factors that
cannot be modified. A personal history of colorectal cancer or inflammatory bowel disease (IBD)—the
risk in patients with ulcerative colitis is increased by 3.7% [14], while people suffering from Crohn’s
disease have a 2.5% higher risk of developing colorectal cancer [15]—are also important risks for
colorectal cancer development,. The chronic inflammation found in IBD often produces an abnormal
cell growth known as dysplasia. Although dysplastic cells are not yet malignant, they have more
chances of becoming anaplastic and developing into a tumour. Another risk factor that can be included
in this group is the presence of a positive familial history of CRC in relatives, especially those relatives
under fifty years of age at diagnosis. An increased risk due to familial history can be derived from
inherited mutations or the environment [16].
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Some other risk factors, which are related to lifestyle, can be reduced by implementing modest
lifestyle changes in terms of dietary and physical activity habits. For instance, it is thought that a
sedentary lifestyle can increase the risk of developing colorectal cancer, although this relationship
between colorectal cancer and inactivity is not completely defined. However, it has been proved that
moderate physical activity increases metabolic rates and gut motility and, in the long term, increases
metabolic efficiency and reduces blood pressure [17].
A sedentary lifestyle is also related with obesity, another important risk factor for colorectal cancer.
Remarkably, this increased risk is linked to both food intake and increased levels of visceral adipose
tissue (VAT), a hormonally active component of total body fat that can promote the development of
colorectal cancer through the secretion of proinflammatory cytokines, which leads to an inflammatory
situation in the colon and rectum, insulin resistance and modulation of metabolic enzymes such as
adiponectin or lectin [18]. In this context, diet is strongly linked to the risk of colorectal cancer such
that unhealthy nutritional habits increase the chances of developing colorectal cancer by up to 70% [19].
For instance, red meat releases heme groups in the intestine, which enhance the formation of carcinogenic
N-nitroso compounds as well as cytotoxic and genotoxic aldehydes by lipoperoxidation [20],
and meat cooked at high temperatures produces heterocyclic amines and polycyclic hydrocarbons after
digestion, both of which are considered to be potential carcinogens [21]. Furthermore, smoking and
alcohol consumption have also been shown to increase CRC risk. In the case of alcohol consumption,
acetaldehyde (the main metabolite of ethanol) has been described as carcinogenic by increasing the
risk of developing colorectal cancer among populations depending on polymorphisms of alcohol
metabolism enzymes [22]. However, the relationship between alcohol consumption and CRC has
not yet been totally elucidated. Tobacco smoking, in turn, can increase the chances of suffering from
CRC by up to 10.8% [23] due to the high content in carcinogens such as nicotine, the metabolites of
which can easily reach the intestine and generate polyps [23,24]. Although smoking increases CRC
risk, a significant relationship has only been found for long-term smokers, whether they have stopped
smoking or not [25].
2.4. Molecular Pathways of Colorectal Cancer
Genomic instability is an important feature underlying colorectal cancer. The pathogenic
mechanisms leading to this situation can be included in three different pathways, namely chromosomal
instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype (CIMP).
The CIN pathway, which is also considered to be the classical pathway since it represents the cause
of up to 80%–85% of all CRC cases [26], is characterized by imbalances in the number of chromosomes,
thus leading to aneuploydic tumours and loss of heterozygosity (LOH). The mechanisms underlying
CIN include alterations in chromosome segregation, telomere dysfunction and DNA damage response,
which affect critical genes involved in the maintenance of correct cell function, such as APC, KRAS,
PI3K and TP53 amongst others. APC mutations cause the translocation of β-catenin to the nucleus
and drive the transcription of genes implicated in tumourigenesis and invasion, whereas mutations in
KRAS and PI3K lead to a constant activation of MAP kinase, thus increasing cell proliferation. Finally,
loss-of-function mutations in TP53, which encodes for p53, the main cell-cycle checkpoint, cause an
uncontrolled entry in the cell cycle [27].
The Microsatellite instability pathway is caused by a hypermutable phenotype due to loss of DNA
repair mechanisms. The ability to repair short DNA chains or tandem repeats (two to five base-pair
repeats) is decreased in tumours with microsatellite instability; therefore, mutations tend to accumulate
in those regions. These mutations can affect non-coding regions as well as codifying microsatellites,
and tumours develop when reading frames of oncogenes or tumour suppressor genes codified in
microsatellites are altered. Loss of expression of mismatch repair genes (MMR) can be caused by
spontaneous events (promoter hypermethylation) or germinal mutations such as those found in Lynch
syndrome. These tumours are mainly diploid and harbour less LOH. Genes mutated in tumours with
microsatellite instability include MLH1, MSH2, MSH6, PMS1 and PMS2 [28]. In general, MSI tumours
have a better prognosis than sporadic tumours [11].
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Epigenetic instability, which is responsible for the CpG island methylator phenotype, is another
common feature in CRC. The main characteristic of CIMP tumours is the hypermethylation of oncogene
promoters, which leads to genetic silencing and a loss of protein expression. Genetics and epigenetics
are not exclusive in colorectal cancer, and both cooperate in its development, with more methylation
events than point mutations often being found [29]. One example of the combined effect of genetics
and epigenetics in the colorectal cancer development process is the presence of BRAF mutations as
well as microsatellite instability in many CIMP tumours [30].
3. New Molecular Discoveries in Colorectal Cancer (CRC)
3.1. Influence of Genomic Aberrations on CRC Outcome
New genomic techniques have allowed the identification of a vast number of genomic aberrations
involved in colorectal cancer. Thus, although mutations are the main genomic alteration, several
chromosomal changes and translocations can also frequently be found in CRC. All of those aberrations
affect important pathways (WNT, MAPK/PI3K, TGF-β) and functions within the cell (TP53 and
cell-cycle regulation) [31] (Figure 2).
The WNT pathway plays a key role in stem-cell differentiation and cellular growth.
Therefore alterations in this pathway may drive tumour development. WNT pathway alterations in
CRC are also associated with weakened tight junctions, which leads to a reduced cellular adhesion and
hence favours migration and metastasis [32]. The main genomic aberration in CRC related to the WNT
pathway is APC mutations, although many other alterations can also target this pathway. Moreover,
genomic alterations in the WNT pathway are not exclusive, and tumours harbouring mutations in APC
may also present other common alterations [31]. Despite being the most common mutated gene, APC
is not a guaranteed prognostic marker for CRC due to the high frequency of mutations among CRC
cases and the wide range of mutations found within this gene [33]. β-Catenin, which is also involved
in the WNT pathway, is also not generally useful for prognosis since it is commonly overexpressed in
CRC cancers [33]. However, overexpression of c-MYC, which is triggered by activation of the WNT
pathway, is considered to be a metastasis marker and good survival-related prognostic factor [34,35].
The MAPK and PI3K pathways are both involved in cell proliferation and survival. Alterations
affecting these pathways therefore confer proliferative advantages on tumour cells. KRAS, BRAF and
PIK3CA (PI3K) mutations are the most common type in CRC. Mutations in KRAS exon 2 codon 13 are
associated with poor prognosis as well as lower survival [36], whereas mutations in exon 2 codon 12
are associated with more advanced tumours and metastasis [37]. In addition to this, BRAF mutations
also have a poor prognosis associated with lower survival rates, especially in those tumours with
microsatellite instability [38–40]. Although BRAF V600E, which is the most common BRAF mutation in
many cancer types, is a poor prognostic factor in metastatic cancer [41], it is nevertheless a promising
target for personalized medicine, and the combination of specific BRAF V600E inhibitors with other
MAPK/PI3K pathway inhibitors has been shown to be more effective for treating metastatic CRC [42].
In contrast, KRAS and other less common BRAF mutations are associated with therapy resistance,
hence monotherapy failure leads to poor prognosis [43]. New combinations with MAPK and PI3K
pathway inhibitors are needed in tumours with mutated KRAS or BRAF, which are exclusive. Although
mutations in PIK3CA are also a common feature in colorectal cancer, the relationship between PIK3CA
and CRC outcome is not as well established as those involving KRAS or BRAF. Nevertheless, PIK3CA
mutations are associated with worse prognosis when accompanied by KRAS mutations [44]. Likewise,
tumours with combined mutations in exons 9 and 20 of PIK3CA have a worse outcome than tumours
harbouring just one of those mutations [45]. In addition, loss of PTEN, which downregulates the PI3K
pathway, in primary tumours is significantly related with an augmented death risk and with poor
survival in metastasis [46].
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Figure 2. Molecular pathways involved in colorectal carcinogenesis. Mutations affecting proteins
involved in WNT (orange), MAPK/PI3K (green), SMAD/TGF-β (blue) or DNA repair (purple)
pathways may enhance cell proliferation and survival, thereby inducing tumoural overgrowth and
initiating carcinogenesis. Arrow-headed lines indicate protein activation whereas bar-headed lines
represent protein inhibition.
The TGF-β pathway, in turn, plays a role in fundamental cellular processes such as growth,
differentiation or apoptos s. However, sp radic mut tio s in TGF-β and its pathw y a e not
particularly common in colorectal cancer, hence they are not significant as prognostic m rke s [33].
Nevertheless, chromosomal changes involving TGF-β are strongly li ked to the CIN pathway in
CRC. Loss of 18q is one of the main ge omic aberrations related to the TGF-β pathway in colorectal
cancer [47]. Chromosome 18q encodes for two important tumour suppressor genes known as SMAD2
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and SMAD4, the loss of which leads to an ability to evade apoptosis and deregulation of the cell cycle.
Current studies demonstrate that there is a weak correlation between poor prognosis/shorter survival
rates and 18q loss. However, further studies including more extensive cohorts may be needed before
18q loss can be considered to be a helpful prognostic marker [48,49].
Finally, TP53 is one of the most important tumour suppressor genes and the main cell-cycle
checkpoint, thus its loss can drive tumour progression by allowing excessive proliferation. Loss of
17q-TP53, which encodes for p53, is a frequent event in CRC as it plays a role in the classical adenoma
to carcinoma succession. Moreover, although an association between TP53 loss and poorer survival
rates have been found, TP53 is not considered a useful prognostic marker since current data are
insufficient for its validation [50].
Additionally, overall genomic context of the tumour is of clinical relevance in CRC. The analysis
of Dukes’ C CRC found that patients with tumours containing more than two aberrations had a
significantly better survival than those with tumours containing two or less aberrations, whereas
genomic analysis found no association between specific chromosomal aberrations and survival [51].
Other studies also demonstrated that increased genetic instability [27] or increased chromosomal
aberrations are associated with a favourable outcome [51]. The underlying mechanisms are still
unclear although it has been suggested that an excess of genomic instability can activate various
mechanisms of cell death.
In consequence, molecular characterization of somatic DNA aberrations is a helpful strategy to
improve prognosis prediction and therapy selection of individual patients, constituting one of the
most important bases for a modern and personalized medicine.
3.2. Role of ncRNA in Colon Carcinoma
Non-coding RNAs (ncRNAs) are RNA molecules transcribed from non-coding regions of the
genome, thus they lack an open reading frame and are not translated into proteins. In the last
few years, several different types of ncRNAs have been identified and associated with several cell
functions. For instance, rRNAs and tRNAs participate in mRNA translation, snoRNAs (small nucleolar
RNAs) are involved in rRNA modifications, snRNAs (small nuclear RNAs) drive splicing and both
miRNAs (micro RNA) and siRNAs (small interfering RNA) regulate gene expression [52]. In this
context, miRNAs have been one of the most studied epigenetics elements involved in cancer due to
their importance in gene-expression regulation. These miRNAs bind to the 3’UTR regions of several
mRNAs, thus inducing their degradation or repressing their translation, consequently associating CRC
with deregulation of different miRNAs (Table 1 and Figure 3).
Table 1. miRNAs involved in colorectal cancer (CRC).
miRNA Name Target Function of miRNA References
miR-34a SIRT1, FMNL2 and E2F5 Inhibition and induction of p53 acetylation [53,54]
miR143 DNMT, KRAS Induction of cell proliferation [55]
miR135 APC Suppression of WNT pathway [55]
miR-29 DNMT 3A and 3B Reduction of methylation [56]
miR-21 PDCD4 Invasion and metastasis promotion [57]
miR-345 BAG Induction of cell proliferation and invasion [58]
miR-148b CCK2R Induction of cell proliferation [59]
Let-7c KRAS, MMP11 and PBX3 Metastasis induction [60]
Let-7a Np95 ICBP90 RING finger Induction of cell proliferation [61]
miR-499-5p FOXO4 and PDCD4 Induction of metastasis [62]
miR-92 KLF4 Promotion of cell growth and migration [63]
miR-126 SPRED1, PIK2R2/P85-β Inhibition of cell proliferation, migration and invasion [64]
miR-320 FOXO4 and PDCD4 Inhibition of cell proliferation [65]
miR-200 family JNK2 Inhibition of tumour growth and metastasis andinduction of sensitivity to chemotherapeutic drugs [66]
miR-9 TM4SF1 Suppression of cell migration and invasion [67]
miR-503 calcium-sensing receptor Induction of proliferation migration and invasion [68]
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Table 1. Cont.
miRNA Name Target Function of miRNA References
miR-222 MST3 Induction of invasion and migration [69]
miR-181b RASSF1A Induce proliferation and enhance cell survival [70]
miR-497 VEGFA Inhibition of invasion and metastasis [71]
miR-152 PIK3R3 Tumour suppressor [72]
miR-187 SOX4, NT5E and PTK6 Inactivation of TGF-β pathway and prevention of EMT(epithelial to mesenchymal transition) [73]
miR-519 Orai1 Tumour suppression [74]
miR-155 HMG-box transcription factor 1 Tumour suppressor by inductionof WNT/β-catenin pathway [75]
miR-497 KSR1 Tumour growth inhibition andenhancement of chemo sensitivity [76]
miR-375 Bcl-2 Inhibition of tumour progression [77]
miR-1246 CCNG2 Induction of cell growth and metastasis [78]
miR-140-5p VEGFA Inhibition of tumour progression [78]
miR-144 GSPT1 Inhibition of proliferation and migration [79]
miR-638 Phospholipase D1 Inhibition of cell proliferation [80]
miR-99b-5p mTOR Inhibition of metastasis formation [66]
miR-101 SphK1 Inhibition of cell growth andincrease of paclitaxel chemo-sensitivity [81]
miR-20a TIMP-2 Induction of epithelial-to-mesenchymaltransition (EMT) [82]
miR-409-3p GAB1 Inhibition of tumour progression and metastasis [83]
Int. J. Mol. Sci. 2017, 18, 197 8 of 37 
miR-222 MST3 Induction of invasion and migration [69] 
miR-181b RASSF1A Induce proliferation and enhance cell survival [70] 
miR-497 VEGFA Inhibition of invasion and metastasis [71] 
miR-152 PIK3R3 Tumour suppressor [72] 
miR-187 SOX4, NT5E and PTK6 
Inactivation of TGF-β pathway and prevention of EMT 
(epithelial to mesenchymal transition) 
[73] 
miR-519 Orai1 Tumour suppression [74] 
miR-155 
HMG-box transcription 
fact r 1 




Tumour growth inhibition and enhancement of chemo 
sensitivity 
[76] 
miR-375 Bcl-2 Inhibition of tumour progression [77] 
miR-1246 CCNG2 Induction of cell growth and metastasis [78] 
miR-140-5p VEGFA Inhibition of tumour progression [78] 
miR-144 GSPT1 Inhibition of proliferation and migration [79] 
miR-638 Phospholipase D1 Inhibition of cell proliferation [80] 
miR-99b-5p mTOR Inhibition of metastasis formation [66] 
miR-101 SphK1 
Inhibition of cell growth and increase of paclitaxel 
chemo-sensitivity 
[81] 
miR-20a TIMP-2 Induction of epithelial-to-mesenchymal transition (EMT) [82] 
miR-409-3p GAB1 Inhibition of tumour progression and metastasis [83] 
 
Figure 3. Schematic representation of the different miRNAs (blue) and lncRNAs (green) involved in 
colorectal carcinogenesis. Arrow-headed lines indicate protein activation whereas bar-headed lines 
represent protein inhibition. 
  
Figure 3. Schematic representation of the different miRNAs (blue) and lncRNAs (green) involved in
colorectal carcinogenesis. Arrow-headed lines indicate protein activation whereas bar-headed lines
represent protein inhibition.
Int. J. Mol. Sci. 2017, 18, 197 9 of 39
One of the latest discoveries in the field of ncRNAs are known as lncRNAs, which are expressed
in many loci of the genome and modulate gene expression in the nucleus and in the cytoplasm.
In the nucleus, they can modify epigenetic markers by activating or suppressing chromatin
modification proteins such as DNMT3A, whereas in the cytoplasm, they can act as a miRNA decoy,
translation regulators or splicing regulators [84]. In consequence, lncRNAs play a critical role in
cellular differentiation and proliferation processes, which are intimately involved in cancer.
Over the last few years, and thanks to the development of high-throughput genome sequencing
tools, new lncRNAs have been associated with cancer in general, and with CRC in particular.
Some of the most important types are presented in Table 2 and Figure 3. Under physiological
conditions, these lncRNAs regulate gene expression, epigenetic imprinting or alternative splicing,
acting as proto-oncogenes or tumour suppressor genes [85]. When lncRNAs act as proto-oncogenes,
their overexpression leads to an upregulation of genes with a critical role in tumour progression,
such as MYC or genes involved in the WNT signalling pathway [86]. Similarly, when acting as tumour
suppressors, lncRNAs regulate the expression of p53-dependent genes under normal conditions.
As such, when the expression of these lncRNAs is decreased, the expression of genes under their control
becomes altered and cells develop resistance to apoptosis, thereby increasing their proliferation [87].
Moreover, as lncRNA alterations remain constant among patients, they could constitute a potential
biomarker for the diagnosis and prognosis of CRC.
The role of ncRNAs can be modified by multiple inherited genetic and epigenetic alterations in
addition to structural variations and transcriptional regulations; all of these factors contribute to their
dysregulation and are implicated in the etiology and pathophysiology of cancer. It is well established
that the dysregulation of ncRNAs alters various cancer-related signalling pathways; however, due to
their complicated structural characteristics, as well as their specific temporal and spatial expression
patterns; further structural, functional, and mechanistic characterizations should be performed to
achieve a better understanding of their particular role in CRC.
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Table 2. LncRNAs involved in CRC.
LncRNA Locus Size (kB) Dysfunction Type Normal Function Contribution to Cancer References
H19 Chr11p15.5 2.3 Overexpression Regulation of growth duringdevelopment targeting Igf2 Downregulation of the tumour suppressor RB [88–90]
HOTAIR Chr12q13.3 2.2 Overexpression Epigenetic silencing of gene expression Reprogramming of chromatin state andinduction of metastatic progression [91,92]
MALAT1 Chr11q13.1 7 Overexpression Alternative splicing regulation
Increase of abnormal mitosis, invasion
and metastasis and induction
of cell death resistance
[93]
HULC Chr6p24.3 0.5 Overexpression
Sponge for miR-372 and indirect
upregulation of PKA and
activation of CREB
Upregulation of Prkacb
(catalytic subunit of PKA) [94]
MEG3 Chr14q32 1.6–1.8 Downregulation
Tumour suppressor. It activates p53,
inhibits cell proliferation and
controls gene imprinting
Downregulation of p53, apoptosis inhibition
and induction of proliferation [95]
CCAT1 Chr8q24.21 2.6 Overexpression
Enhancer region for cMYC. Maintenance of
the chromatin looping between MYC
promoter and its enhancer
Induction of MYC expression and
inhibition of G1 arrest. Enhancement
cell proliferation and migration
[96,97]
CCAT2 Chr8q24 0.4 Overexpression SNP rs6983267 Upregulation of MYC and enhancement ofWNT signalling pathway through TCF7L2
Induction of cell proliferation, invasion
and chromosomal instability [98]
CRNDE Chr16:hCG_1815491 10 Overexpression Scaffold for regulatory complexes Contribution to Warburg effect.Increase of CRC risk [99]
LOC285194 Chr3q13.31 2.1 Downregulation Unknown Decrease of cell migration and metastasis [100]
OCC-1 Chr12121.1 1.2–1.3 Overexpression Unknown Induction of cell proliferationand apoptosis resistance [101]
lincRNA-p21 - 3.1 Downregulation
Binds to hnRNP-K and repress genes
transcriptionally regulated by p53. It is
necessary for p53-dependent apoptotic
induction but not for cell-cycle arrest
Induction of apoptosis evasion, invasion and
enhancement of Warburg effect [102]
LIT1 Chr11q15.5 91 Loss of imprinting
Organization of a tissue/lineage-specific
nuclear domain involved in epigenetic
silencing of the Kcnq1 imprinting control
region
Unknown [103]
PTENP1 Chr9q13.3 3.9 Downregulation Decoy for miRNA targeting PTEN Reduction of PTEN level andenhancement of cell growth [104]
MYLKP1 Chr3p12.3 106 Overexpression Pseudogen Induction of proliferation [105]
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Table 2. Cont.
LncRNA Locus Size (kB) Dysfunction Type Normal Function Contribution to Cancer References
pou5f1p1 (OCT4) Chr8q24 0.4 Overexpression Pseudogen Increased of risk of CRC [106]
UCA1 Chr19p13.12 1.4, 2.2, 2.7 Overexpression Embryonic development Induction of resistance todrug-induced apoptosis [107]
PCAT1 Chr8p24 1.9 Overexpression BRCA2 inhibition
Regulation of cell response to genotoxic stress
and impairing of DNA damage repair. High
levels are associated with poorer survival rate
[108–110]
PRNCR1 Chr8p24 13 Overexpression




Increase of cell proliferation [72,111,112]
LET Chr15q24.1 2.3 Downregulation
Downregulation of hypoxia signalling by
decreasing HIF1 stability. Induction of NF90
ubiquitination and Go/G1 arrest
Induction of metastasis [113]
ncRAN Chr17q25.1 2.3 Overexpression Unknown Enhancement of cell migration and invasion [114]
PVT1 Chr8p24.21 >300 Overexpression Regulation of C-MYC Anti-apoptotic activity. Increase of cellproliferation and cell-cycle progression [115,116]
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Furthermore, a growing number of studies have reported that ncRNAs could function as potential
diagnostic and prognostic biomarkers for CRC in stool, serum, plasma, and tissues. As we will develop
in the biomarkers section, the most commonly used screening methods for CRC such as colonoscopy
and the fecal occult blood test are limited by their invasiveness, low specificity and sensitivity and
high cost. Therefore, ncRNAs, thanks to their tissue-specific signature and their particular expression
pattern in tumour, have emerged as a great promise for the development of accurate and non-invasive
biomarkers for early CRC detection and prognosis prediction. For instance, certain 12 miRNAs
(such as miR-7, -17, -20a, -21, -92a, -96, -106a, -134, -183, -196a, -199a-3p, and -214) showed higher
expression levels in stool samples from CRC patients than in those from healthy controls, whereas eight
miRNAs (miR-9, -29b, -127-5p, -138, -143, -146a, -222, and -938) were shown to be downregulated [117].
Circulating miRNA, can also constitute important biomarkers for CRC screening and prognostic
evaluation. Alterations in blood-based miRNAs has been also detected in CRC patients, and they
appear to be more sensitive but less specific than fecal miRNAs for the diagnosis of CRC.
However, although several studies have demonstrated the association between certain ncRNA
and clinicopathological characteristics, several limitations prevent their use in the clinic. First, the levels
of circulating ncRNA transcripts and their post-transcriptional modifications are unstable and variable
or even difficult to detect during different stages of the disease. Second, there is not a simple standard
assay or consensus in an endogenous control for the quantification of circulating ncRNAs. Third,
most of the obtained results have not been replicated and, moreover, ncRNA-based diagnoses appear
to be more accurate in Asian than in Caucasian patients [118]. In consequence, the actual results need
to be confirmed in multiple studies with larger-scale validation across multiple centers and different
populations. Finally, it is difficult to determine the origins of circulating ncRNAs that have been
isolated and quantified, and hence it is hard to determine whether these ncRNAs are secreted from
cells of tumour tissues or whether they are detected as a consequence of hematocyte contamination.
Besides their potential use as biomarkers, the capacity of ncRNAs to regulate gene expression in
general and in gene networks involved in cancer cell transformation in particular, make them a highly
attractive therapy against CRC. However, several challenges should be overcome for their use in the
clinic such as lack of reliable delivery methods, limited effective vector for ncRNA delivery inside
cells, lack of optimal dosage regimes, and determination of side effect. In consequence, novel effective
and stable strategies for genome editing, as well as more efficient and less toxic gene therapy delivery
systems need to be developed before ncRNA can constitute a potential treatment for CRC.
3.3. Gut Microbiome in CRC
The human body contains more than 100 trillion microbes [119], most of which are hosted
in the gut, although there are different communities residing in a vast range of body niches [120].
This population is called the microbiome and comprises a wide variety of microorganisms, including
archaea, viruses and fungi, although anaerobic bacteria is the most studied group since they are the
most abundant [121–123]. These microbial communities are acquired at birth [124] and are essential
for maintaining body homeostasis.
The gut microbiome comprises an estimated microorganism load of 1013–1014 belonging to more
than 1000 different bacterial species. The interaction between the host and the microbiome is dynamic
and controlled by a huge number of genetic and environmental factors, such as age, geography,
alcohol or drug intake and diet [125–128]. Thus, although intestinal microbiota have been shown to be
individual and variable over time, only two predominant phyla, namely Firmicutes and Bacteroidetes,
comprise over 90% of all endogenous bacteria present in healthy adults. Other members of the
normal colonic microbiome include Eubacterium, Bifidobacterium, Fusobacterium, Lactobacilli, Enterococci,
Streptococci or Enterobacteriaceae [129–131]. The composition of the microbiome is mainly studied using
rRNA sequences as traditional culture methods are inadequate in most cases [131–133].
Intestinal microorganisms play a critical role in human physiology and metabolism, with their
responsibilities including the synthesis of essential vitamins like vitamin K, the extraction of energy
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from indigestible carbohydrates such as pectins, modulation of the human immune system and the
prevention of colonization by enteropathogenic bacteria [119,134–136]. In return, these commensal
bacteria take advantage of a unique environment with an adequate pH range and oxygen concentration
which is also abundant in nutrients.
Given its vast importance, it is not surprising that alterations in normal flora cause serious
problems. For instance, the condition known as dysbiosis, in which the natural relationship between the
host and the intestinal microbiota is disrupted [137–140], is considered to be one of the most probable
causes of inflammatory bowel disease (IBD) [141–144] or colorectal cancer (CRC) [142,144–147].
Many factors, such as antibiotic treatment or some types of diet, are known to be involved in the
development of dysbiosis [139,148,149].
3.4. Dysbiosis and Colorectal Cancer: Breaking the Mutualism
Although it is not yet clear how dysbiosis could induce colonic carcinogenesis, chronic
inflammation appears to be the main mechanism. This hypothesis is supported by the fact that
many types of cancer are caused by chronic inflammation [150,151]. For example, inflammatory bowel
diseases (IBD) are linked to an increased risk of colon cancer [144,152]. The first stages of these diseases
involve an alteration to the normal flora, which results in activation of the immune system, thus giving
rise to the inflammation that characterizes IBD. As IBD patients have a higher probability of suffering
CRC, and dysbiosis has been observed in some cases [142–144], it is possible to assume that IBD-related
CRC is driven by a previous dysbiosis stage.
As a result, the microbiome has started to be considered one of the prime suspects responsible for
the onset and/or evolution of colonic carcinogenesis. This research field is based on the differences
found in microbial signature between CRC patients and healthy populations. Indeed, next-generation
sequencing methods based on 16s rRNA have revealed an enrichment in proinflammatory bacteria,
such as Fusobacterium, which is also overrepresented in other diseases (for example IBD), as well as a
lower abundance of butyrate producers, such as protective bifidobacteria [145,147].
It is thought that proinflammatory bacteria could inhibit, disturb or exacerbate normal host
responses, thus leading to abnormal apoptosis, cell proliferation and inflammation. Another proposed
mechanism for the onset of CRC is the presence of bacterial secondary metabolites, such as reactive
oxygen intermediates or some kinds of toxins, which can damage host DNA and induce cell
transformation [153–157]. However, it remains unknown whether a specific bacterium, a microbial
community, or both, acting sequentially or synergistically, are responsible for CRC. A deeper
understanding of the role of microbiota in the onset of CRC could result in an important prevention
tool, since analysis of microbial population in feces would help to predict the risk of suffering from
CRC. Moreover, the results of these studies might lead to the establishment of a set of lifestyle changes
that contribute to reducing the risk of developing CRC. Therefore, with the coordinated action of
oncologists and endocrinologists, the number of patients affected by CRC could be drastically reduced.
Despite this, researchers have focused on some members of the microbiota as the prime suspects in
this multiphase process. In this context, some of the most studied microorganisms are discussed below.
3.4.1. Fusobacterium spp
Fusobacterium spp comprises a group of anaerobic gram-negative non-spore-forming bacteria
commonly found in the oral and intestinal human flora. This bacterial genus displays high
heterogeneity and some of its members, such as F. nucleatum, the presence of which is increased
in CRC samples, have been associated with pathological diseases [158].
Flanagan and colleagues [159] conducted a study using three European cancer cohorts to compare
F. nucleatum levels in normal tissue and in tumour tissue. They found an enrichment of F. nucleatum
in tumour tissue from all cancer cohorts, with an over-representation in precancerous adenomas.
Interestingly, they also observed a significant correlation between survival and F. nucleatum levels
in tumour tissue, with higher F. nucleatum abundances correlating with a worse prognosis. Similar
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studies were realized in other parts of the world as, for example Kostic [159] in the United States or
Li [160] in China, with analogous results being found in each case.
The role of F. nucleatum in tumour development and progression may be related to its proliferative
and immunosuppressive effects. The abundance of these bacteria in tumour tissue is directly correlated
with an increased production of proinflammatory cytokines such as IL-6, IL-12, IL-17 or TNF-α [161],
which is consistent with the upregulation of nuclear factor kappa B (NF-κB) [159]. Similarly,
F. nucleatum contributes to colon carcinogenesis by releasing short peptides and short-chain fatty acids,
which recruit myeloid-derived suppressor cells, thereby suppressing CD4+ T-cell activity. Finally,
they can avoid tumour cell lysis mediated by NK cells via their Fap2 protein. Fap2 is able to interact
with the T cell immunoglobulin and ITIM (TIGIT domain) receptor of NK cells and, as a result,
inhibit their cytotoxic potential [162].
3.4.2. Bacteroides Fragilis
Two classes of B. fragilis that could colonize the human gut have been described. These classes
are distinguished by their ability to produce a heat-labile toxin or not. This toxin, called B. fragilis
toxin, or simply BFT, is a zinc-dependent metalloprotease that is able to induce inflammation due to its
ability to stimulate the production of IL-18, a proinflammatory cytokine. In addition, BFT can clear
E-cadherin and, as a consequence, disturb epithelial homeostasis, thus leading to colonic epithelial
proliferation and possibly resulting in the onset of colorectal cancer [163,164].
In light of the above, a prevalence of toxigenic B. fragilis in the normal flora could be related to a
higher risk of malignant transformation of the enterocytes. Toprak and colleagues were the first to
compare the abundance of this bacteria between CRC patients and those with no colorectal disease,
both groups being Caucasian, finding significantly higher levels of toxigenic B. fragilis in the former.
Similar results were obtained more recently by other researchers. For example, Boleij and colleagues
observed that BFT gene prevalence was associated with CRC upon comparing mucosal samples from
the Johns Hopkins Hospital [164].
3.4.3. Enteropathogenic Escherichia coli
E. coli is a commensal bacterium widely found throughout the human gut. However, some strains
may be linked to the onset of CRC. Thus, phylogroups B2 and D are commonly found to be responsible
for some intestinal diseases because of their production of bacteriocins. Indeed, levels of these strains
have been found to be significantly increased in CRC samples [165].
The bacteriocin colibactin, the production of which might lead to a higher risk of malignant
transformation, is a hybrid nonribosomal peptide-polyketide encoded by the 54 kDa polyketide
synthase (pks) genotoxicity island. The pro-tumour properties of this bacteriocin are related to its
ability to cause DNA double-strand breaks and chromosomal instability [166,167].
3.5. Microbiome and Diet: A Possible Link with CRC
As CRC incidence is rapidly increasing in regions where it was previously not a problem, such
as Eastern Asia or Eastern Europe and Mediterranean countries [168–170], it is thought that dietary
changes are mainly responsible for this trend. Although large quantities of fruit and vegetables used
to be consumed in these regions, food consumption habits have recently turned towards a more
“Western diet” characterized by a high abundance of red meat and fat [171].
Although meat consumption has increased at the same time as colon cancer incidence,
this correlation does not necessarily imply causation. However, some mechanisms that could explain
this relation have been proposed, including N-nitroso compounds (NOCs), heterocyclic amines and
polycyclic aromatic hydrocarbons or heme iron [172]. Nevertheless, one of the most interesting effects
of high red meat and processed meat consumption is the consistent changes in gut microbiome
composition, which leads to an enrichment in harmful bacteria [173].
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In this regard, studies by Ou and colleagues [174], who compared samples from rural Africans
with African Americans, revealed that microbiome composition is greatly influenced by dietary
patterns. Thus, although both groups belonged to the same ethnicity, their microbiomes were
significantly different, with Prevotella, Succinivibrio and Oscillospira predominating in African samples
and Bacteroidetes such as B. fragilis predominating in African Americans. These differences could be
explained by the fact that African Americans tend to eat more red meat and fat than rural Africans.
Feng and colleagues [175] took this supposition to the next level: by comparing samples from CRC
patients with different dietary patterns. Using a metagenomic analysis, they discovered that those
bacteria whose populations were higher in CRC samples (for example B. massiliensis, P. merdae,
A. finegoldii or B. wadsworthia) were found at lower levels in those subjects whose fruit and vegetable
intake was abundant; in contrast, they were elevated in high red meat consumers.
In addition to high meat consumption, a diet rich in fat could also be responsible for increasing
CRC risk. Thus, O’Keefe and colleagues [176] studied CRC samples from African Americans and rural
Africans and found lower levels of butyrate producers in African Americans compared with rural
Africans. As the antitumour properties of butyrate are well established [177,178], this fact could explain
the higher incidence in response to a diet rich in fat. Moreover, a high fat intake is also related to higher
expression of the microbial genes involved in deconjugation of bile acids and production of secondary
bile acids [176]. Secondary bile acids such as lithocholic acid are considered to be tumour-promoting
agents due to their ability to induce oxidative stress, DNA damage or mutation [66]. Taken together,
these two factors could explain why a high fat intake leads to the onset of colon cancer.
However, if diet is the problem it could also be the solution. Thus, the study of O’Keefe [176],
for example, shows that a diet rich in fiber leads to higher butyrate production. Donohoe and
colleagues [179] developed a BALB/c inbred mouse model polyassociated with four commensal
bacteria plus or minus the butyrate producer Butyrivibrio fibrisolvens to show that fiber intake could
protect against CRC via microbiome butyrate production. These mice were fed with identical and
calorically matched low- or high-fiber diets; as expected, the animals given the higher amount of
fiber produced the most butyrate. Upon injection of tumour-promoting agents, mice colonized with
B. fibriosolvens and fed with the high-fiber diet were less sensitive to tumour development, thus proving
the protective effect of butyrate in CRC.
4. Recent Advances in CRC Diagnosis and Staging
4.1. Use of Biomarkers in CRC
A biomarker is a biological entity that can be used to measure the presence or progression of a
particular disease or the effects of treatment. Biomarkers must possess several important characteristics,
such as high sensitivity, specificity, and safety, in addition to being easy to measure and useful for
establishing an accurate diagnosis and facilitating treatment selection [180].
As noted previously, three major alterations, namely microsatellite instability (MSI), chromosomal
instability (CIN) and the CpG island methylator phenotype (CIMP), are found in CRC. These alterations
produce modifications in DNA, RNA, proteins or metabolites, which can be measured in the tumour
specimen, blood or stool and can therefore be used as biomarkers [181]. Some of the most important
biomarkers for CRC, and their clinical use, are summarized in Table 3. In contrast to the methods
presently used (colonoscopy, sigmoidoscopy, double contrast barium enema, computer tomographic
colonoscopy and fecal blood test (FOBT)), molecular tests are expected to be more specific, sensitive
and better tolerated by patients, although further studies are needed for their validation.
The most widely used biomarkers in CRC are currently the determination of MSI and KRAS
mutations in tumour samples in order to classify the tumour, make a prognosis of the disease and
manage therapy [181]. Although other biomarkers, including the determination of FOBT and CEA,
are used for diagnosis, they tend to exhibit high specificity but very low sensitivity [182]. This is the
main reason why researchers are searching for better molecules for the early diagnosis of CRC. In this
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context, the most remarkable findings include the use of kits to evaluate the CpG island methylator
phenotype, miRNA and gene microarrays which can be detected in stool or blood. Most of these kits
are under clinical evaluation and have a promising future.
Considering the limitation of the actual screening methods for CRC—invasiveness, low specificity
and sensitivity and high cost—the identification of new molecular biomarkers with predictive and/or
prognostic significance in CRC has become an essential issue to improve anti-cancer treatments
and patient outcome. Over the past two decades, several molecular biomarkers have been studied
and the obtained results are encouraging; however, several drawbacks affect the reliability of the
conclusions [145]. First, most of the published studies were retrospective analyses of a single marker
or included a small sample size, and, in consequence, predictions lack resolution and reproducibility.
Second, data analysis and interpretation remain challenging; data obtained usually lack definition
and adequate validation, and are thus not reliable enough to be used in clinical practice. Furthermore,
the lack of methodology for standardization, as well as the absence of standardized endogenous
controls, make it difficult to quantify and validate the obtained results.
In consequence, although the number of potential biomarkers is large, only the KRAS gene has
entered routine clinical practice, and it is used as a predictive marker of response to EGFR-targeted
therapies in advanced CRC stages. Nevertheless, a great deal of effort is being focused on this issue,
and despite all their actual disadvantages, the use of biomarkers have a promising future in the
diagnosis and prognosis of CRC, as well as in the development of personalized and targeted therapy.
Int. J. Mol. Sci. 2017, 18, 197 17 of 39
Table 3. Current biomarkers for CRC.
Molecular Marker Type Biomarker Contribution to Cancer Predictive Use Samples Used for the Test Status References
DNA
Microsatellite instability (MSI)
test. Panel of mononucleotide
marker (Bat-25, Bat-26, NR-21,
NR-24, MONO-27), ≥30% of





For MSI+ tumours: Prognosis:
good, aggressively: low, treatment:
lack of response to 5-FU,
good response to irinotecan






If mutated: Prognosis: bad and
poor survival (codon 12 and 13).












If mutated: Classification of CRC:
sporadic, Prognosis: poor,
Treatment: limited response to
EGFR-targeted therapy.







Classification of CRC in CIMP,





and in use for stool
[192,193]
Integrity of cell-free
DNA (cfDNA) Apoptosis Diagnosis and monitoring Blood sample Under evaluation [194]
RNA
gene microarray and




stool, blood Clinical validation [195,196]
miRNA biomarker panel.
e.g., miR-21, miR-106a Unknown Diagnosis and prognosis
Tumour-based samples,
stool, blood Clinical validation [197,198]











Calprotectin, CEA, DAF, CA19-9
Unknown Diagnosis, prognosis, monitoring Stool, blood Clinical validation [202–206]
Others Circulating nucleic acids,proteins and tumour cells Unknown Diagnosis, monitoring Blood Clinical validation [207–209]
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4.2. Gene-Expression Profiling (GEP)
Gene-expression profiling (GEP)-based studies compare gene expression in normal and tumoural
tissue samples or samples from different stages of the disease [210]. It is thought that these comparisons
can provide useful information about the prognosis of the disease and the most suitable treatment for
each patient. Several GEP techniques are currently available from CLIA-certified laboratories (Table 4),
with these differing in terms of the type of assay used and the number of genes studied.
However, despite the number of GEP assays that have appeared in the last years, and their
potential benefits for both patients (reduction of harm and side effects of adjuvant therapies) and
society (lower care costs for patients who will not benefit from adjuvant therapies), the National
Comprehensive Cancer Network (NCCN, 2015) has stated that there is still insufficient evidence
regarding their predictive value in terms of the potential benefit of chemotherapy to any of the
available multigene assays. Moreover, the NCCN has determined that not enough data are available
to base the choice of adjuvant therapy on these assays, hence further studies in this field should be
conducted to address their diagnostic and clinical validity.
Table 4. Current Gene-Expression Profiling (GEP) for CRC.












Redwood City, CA, USA)
Prediction of recurrence in
individuals with stage II
CRC following surgery
7 Genes associated with CRC
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Ann Arbor, MI, USA)
Risk of recurrence of
cancer in individuals of
stage I or II colon cancer or
stage I rectal cancer.
BMI1, ETV6, H3F3B, RPS10 qRT-PCR [219,220]
Previstage (DiagnoCure,
Quebec City, QC, Canada)
Identification of patients
with low risk of recurrence Quantification of GCC mRNA qRT-PCR [221]
5. Novel Therapies for the Treatment of CRC
5.1. Current Treatments for CRC
The choice of first-line treatment for CRC patients currently involves a multimodal approach based
on tumour-related characteristics (e.g., number and localization of metastases, tumour progression,
presence or absence of biochemical markers, etc.) and patient-related factors (e.g., co-morbidity,
prognosis, etc.). In practice, all these aspects are used to classify CRC patients into one of four different
risk groups that will be used to guide the treatment strategy: Group 0: Patients with no metastatic
disease or with resectable liver or lung metastases and lack of poor prognostic signs (e.g., relapse
during adjuvant treatment). In this case, the recommended treatment consists of surgical resection
of the metastasis. Chemotherapy has not been found to provide a great advantage in the overall
survival of this group; Group 1: Patients with potentially resectable metastatic disease. These patients
are initially treated with induction chemotherapy to reduce the number and size of the metastases
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and enable subsequent surgical resection. Recommended chemotherapy for these cases comprises
cytotoxic doublet or triplet, which may be combined with anti-VEGF or anti-EGFR strategies in KRAS
wild-type tumours [222,223]; Group 2: Patients with disseminated unresectable disease. Treatment
selected for this group of patients will be palliative rather than curative, with the main intention of
reducing the symptoms, aggressiveness and extension of the disease. As such, the first-line treatment
selected should induce metastatic regression in a short time. To that end, the preferred option usually
comprises a cytotoxic doublet in combination with a targeted agent (anti-VEGF or anti-EGFR strategies).
In oligometastatic patients who respond to treatment, additional ablative methods may be considered
to increase the progression-free interval. If ablative methods cannot be used, de-escalation of the initial
combination should be studied as a maintenance treatment. In certain cases, complete discontinuation
of the treatment can be considered [222,223]; Group 3: Patients with unresectable disease and lack
of intensive or sequential treatment: In patients lacking symptoms with low risk of deterioration,
the purpose of the treatment will be to prevent tumour progression and increase treatment-free life.
The most commonly used strategies comprise a fluoropyrimidine as cytotoxic agent combined, or not,
with a biological targeted agent [222,223].
As mentioned above, most CRC patients with metastatic disease are treated with a combination of
cytotoxic and targeted biological agents. First-line chemotherapy with palliative purposes comprises
fluoropyrimidines (e.g., 5-fluorouracil (5-FU) or capecitabine) alone or combined with leucovorin
(LV) as well as other cytotoxic agents, such as oxaliplatin (5-FU/LV/oxaliplatin (FOLFOX) and
capecitabine/LV/oxaliplatin (CAPOX)) or irinotecan (5-FU/LV/irinotecan (FOLFIRI)). The use of
leucovorin reduces the toxicity of the treatment, whereas the addition of other cytotoxic agents has
been shown to increase the response rate and progression-free survival, although the toxic effects of
the treatment are also intensified [223,224].
Second-line chemotherapy will be offered to patients with good organ function and should
be selected according to a refractory-based regimen. Second-line treatment for patients refractory
to irinotecan will consist of an oxaliplatin-containing combination such as FOLFOX or CAPOX,
whereas patients refractory to FOLFOX or CAPOX will be treated with irinotecan monotherapy or
FOLFIRI [224].
The optimal duration of chemotherapy treatment depends on each case, with three different
options being available: fixed treatment for 3–6 months, induction treatment followed by a maintenance
treatment, or treatment until toxicity or progression [223].
In addition to chemotherapy, monoclonal antibodies or proteins against vascular endothelial
growth factor (VEGF) and epidermal growth receptor (EGFR) combined with traditional chemotherapy
have been demonstrated to improve the outcome of mCRC [223]. The most commonly used anti-VEGF
strategies are the monoclonal antibody Bevacizumab, which targets circulating VEGF-A, and the
recombinant fusion protein Aflibercept, which blocks VEGF-A, VEGF-B and placental growth factors.
When combined with cytotoxic agents, they represent a first-line treatment for almost all CRC patients.
In contrast, anti-EGFR treatment can only be used in the absence of KRAS mutations, either as a
single agent or combined with cytotoxic molecules. The most important anti-EGFR agents comprise
monoclonal antibodies such as Cetoximab or Panitumumab [223].
Besides traditional chemotherapy, alternative therapies are being studied with the aim of
increasing treatment efficacy and reducing side effects as well as the risk of developing secondary
tumours. The most important research lines currently in progress are the use of agarose tumour
macrobeads, anti-inflammatory drugs, probiotics, and gold-based drugs.
5.2. Agarose Macrobeads
Organs and tumours grow following a Gompertzian curve, a decremented exponential curve that
approaches an asymptote or decreases as enlarged. This evidence suggests that tumours, like organs,
are susceptible to both positive and negative growth-regulatory controls [225]. The positive regulation
of tumour growth is well established and there is a large body of evidence in the literature to support
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this. For instance, it has been shown that the partial surgical removal of a tumour often induces tumour
progression caused by a phenomenon called “compensatory hyperplasia” [226]. Similarly, biological
signals indicating the presence of a tumour mass reduce or stop tumour growth even when that mass
of cells is not present [226]. This hypothesis constitutes the basis for the use of hydrophilic agarose
macrobead culture cells for CRC outgrowth.
Agarose macrobeads consist of two concentric layers of agarose, which create an inner space
where cancer cells can be contained [227,228]. Various tumour cell lines have the ability to form
colonies after encapsulation in agarose macrobeads, but for this application in particular, RENCA
cells (a mouse renal cortical adenocarcinoma cell line) have been selected. After encapsulation,
these cells form one-cell colonies that expand in size up to colonies containing several hundreds of cells.
As the colonies enlarge, their growth slows until they acquire a stable size, which occurs around 6 to
24 months after encapsulation. During this time, the encapsulated cells undergo a transformation
process in which at least two subpopulations of cells are selected to form the tumour colonies [227].
The growth-restrictive agarose environment induces the production of tumour inhibitory molecules,
which are able to inhibit the proliferation of non-encapsulated cancer cells both in vitro and
in vivo [227]. These include the proteins Gelsoin (GSN), Fibulin (FBLN1), nucleolin (NCL),
Prosaposin (PSAP), pigment epithelium-derived factor (PEDF), Serpine1 (Serbp1), secreted protein
acidic and rich in cysteine (SPARC), tissue inhibitor of metalloproteinase 2 (TIMP2), phosphatidyl
ethanolamine-binding protein (PEBP1), and peroxiredoxin 1 (PRDX1) [227]. Although the mechanism
of growth inhibition by RENCA macrobeads is not yet clear, it is thought that all these secreted
proteins generate multiple signals, which end up increasing the cell-cycle time of the exposed cancer
cells. In particular, the results of different experiments demonstrate that RENCA macrobeads extend
the S-phase cycle time and decrease the mitosis number. As the mechanism of action of RENCA
macrobeads is quite nonspecific, this regulatory system is applicable to many epithelial-derived
tumour types from different species and cell lines [227].
RENCA macrobeads have been tested in advanced epithelial-derived cancer in a phase I/II clinical
trial. In general, RENCA macrobeads were well tolerated by patients. Some common adverse effects
were fatigue and anorexia lasting from a few days to three weeks. Other less-common adverse effects
were abdominal pain, constipation, pyrexia, nausea, vomiting, dyspnea, localized fluid accumulation
around the MBs, ascites, abdominal distension and peripheral oedema. Most of the treated patients
showed a positive response to treatment, including a reduction in tumour markers, disease stabilization,
reduction of pain and improvement in quality of life [51,229]. A phase II/III clinical trial is currently
underway and the future perspectives for this treatment are quite encouraging.
5.3. Anti-Inflammatory Drugs
Chronic inflammation, a common feature in colorectal cancer, is caused by immune cells and their
products (cytokines and chemokines), reactive oxygen and nitrogen species (ROS and RNS) and also
some arachidonic acid derivatives, mainly produced via the cyclooxygenase (COX) and lipoxygenase
(LOX) pathways. This inflammation state collaborates in tumour growth, proliferation, invasion and
resistance [230].
Since inflammation is known to play an important part in the generation and progression of
colorectal cancer, many anti-inflammatory drugs have become important in the prevention and
treatment of CRC. Most of the anti-inflammatory agents used are non-steroidal anti-inflammatory
drugs (NSAIDs), which inhibit COX enzymes, thereby blocking the synthesis of arachidonic acid
derivatives. For example, aspirin has demonstrated good results in the prevention of CRC, reducing
risk by up to 50% [231]. Another example of an NSAID used in CRC-derived inflammation is
sulindac [232], which has been shown to reduce colorectal cancer inflammation. Moreover, sulindac
combined with atorvastatin has even been proved to inhibit tumour growth [233].
Despite their anti-inflammatory properties, NSAIDs have negative side effects such as
gastrointestinal ulcerations or kidney damage [234], hence they are mostly used to prevent CRC
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in high-risk patients, such as those with Crohn’s disease, ulcerative colitis or FAP, rather than for
treatment. To avoid these side effects, a new kind of NSAIDs that specifically inhibits cyclooxygenase
2 (COXibs) has been developed to both prevent and treat CRC [235]. Although they do not affect
the gastrointestinal system, some of these compounds, such as rofecoxib, which was withdrawn
from the market in 2004, can produce cardiovascular toxicity [236]. The most important drug within
this group of COXibs is celecoxib, which has been demonstrated to prevent colorectal cancer and
reduce adenomas, even those in advanced states. Moreover, celecoxib does not present adverse
gastrointestinal effects [237] and does not produce cardiovascular problems [238]. In addition,
new formulations are being studied to further reduce the known side effects. One example of these
new drugs is celecoxib microbeads, which only target colon cells. This formulation is currently being
tested using in vitro models, with studies in animal models expected in the near future [239]. Celecoxib
has also been tested in combination with curcumin, a product of curcuma, obtaining a synergistic
anticancer effect [240].
5.4. Probiotics
Having demonstrated the role of microbiota in colorectal cancer onset and progression,
it is legitimate to suppose that it could be switched to a “non-carcinogenic” microbiome, thereby
avoiding the tumourigenic process. In that regard, probiotics are a potential treatment for CRC,
being important for its prevention, and can be used as adjuvants for conventional treatments.
Probiotics are viable microorganisms which, when administered in appropriate quantities, confer
a health benefit on the host. Lactic acid bacteria, including Lactobacillus, Streptococcus, Enterococcus,
Lactococcus, Bifidobacterium and Leuconostoc, are the most studied probiotics in CRC treatment [241–243].
The protective role of probiotics is based on the hypothesis that dysbiosis is the main cause of CRC.
As has been discussed previously, differences in the microbial signature of CRC patients and healthy
controls lead us to the hypothesis that probiotics could help to restore the normal flora and hence
avoid CRC. In order to assess this hypothesis, Pala and colleagues [244] designed a study to correlate
yogurt consumption and CRC risk involving 45,241 healthy volunteers whose dietary patterns and
other lifestyle aspects were carefully analysed. These authors found that yogurt intake was directly
related to a lower CRC risk when considering other lifestyle variables as well, such as whether yogurt
was ingested alone or in combination with other dairy products.
Insights into the mechanism of action of probiotics have mainly been obtained using animal
models given the difficulty of working with human subjects. For example, Chen and colleagues [245]
used a mouse model of colon cancer to investigate the role of orally administered Lactobacillus
acidophilus and found that these bacteria could reduce the harmfulness of the disease by inducing
apoptosis. According to results obtained by Choi and colleagues, this ability to promote cell death
might be related to soluble polysaccharides [246].
Apart from their apoptosis-enhancing activity, probiotics play an important role in CRC
prevention due to their antioxidant potential. Thus, Sah and colleagues [247] demonstrated that
some probiotic strains present in yogurts are able to produce antioxidant peptides with free radical
scavenging activity, meaning that they may reduce oxidative stress in the lumen and, as a consequence,
prevent or delay the onset of CRC.
5.5. Functional Foods
Reactive oxygen species (ROS) are oxygen molecules with a missing or unpaired electron produced
as a consequence of cellular metabolism. At low concentrations, ROS play a physiological role in the
defence against pathogens, the mitogenic response and in different molecular pathways [248–250].
However, an excess of these reactive compounds, which can be induced by environmental pollution
and tobacco or drug consumption, amongst other stressors, can damage different cell structures via the
oxidation of lipids, proteins and DNA [251]. These situations have been associated with several human
diseases, such as arthritis or cancer [252]. As a consequence, maintaining and re-establishing the redox
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balance is critical for the correct functioning of the whole organism, hence redox and antioxidant
systems are amongst the most promising targets in functional food science [253–255]. In this context,
polyphenols obtained from natural sources have emerged as a new strategy to protect cells against
oxidative stress.
Polyphenolic compounds are the most abundant secondary metabolites found in plants [256].
Many foods and food material contain polyphenols, including cereals and legumes (barley, corn, nuts,
oats, rice, sorghum, wheat, beans, and pulses), oilseeds (rapeseed, canola, flaxseed, and olive seeds),
fruit and vegetables, and beverages (fruit juices, tea, coffee, cocoa, beer, and wine) [256,257]. All of them
possess an aromatic ring bearing one or more hydroxyl groups [255]. These polyphenolic substances
or polyphenols include many classes of compounds, ranging from phenolic acids to coloured
anthocyanins, simple flavonoids and complex flavonoids [258]. In addition to anticarcinogenic effects,
all these polyphenols have a strong antioxidant power, thereby decreasing the risk of cancer [259].
Indeed, many polyphenols have been shown to have chemoprotective, antiproliferative, antioxidative
and estrogenic/antiestrogenic activity in addition to inducing cell-cycle arrest or apoptosis and
the detoxification of enzymes. They are also known to regulate the host’s immune system and
changes in cellular signalling [260]. In particular, proanthocyanidins, flavonoids, resveratrol, tannins,
epigallocatechin-3-gallate, gallic acid, anthocyanins and some plant extracts have shown protective
effects in some cancer models [261,262].
5.6. Metal-Based Drugs for CRC Treatment
The use of metals for therapeutic purposes dates back to ancient times. For example, cinnabar
powder, a derivative of mercury, was widely used in traditional Chinese and Indian medicine [263];
silver sulfadiazine is commonly found in topical creams for burn treatment [264], and Tianmai
Xiaoke Tablet, the main ingredient of which is chromium picolinate, is used in China to treat
type 2 diabetes [265]. However, one of the most important achievements for inorganic chemistry in
medicine is the discovery of cisplatin. The anticancer properties of cis-PtCl2(NH3)2, or cisplatin [266],
were discovered accidentally in the 1960s. Since then, many other metal-containing compounds
have been developed in order to treat cancer [267–270]. Herein we will discuss the most promising
candidates, namely platinum and gold, and their use in colorectal cancer chemotherapy.
5.6.1. Platinum
Cisplatin was the pioneer in the use of metals in chemotherapy. This compound has been found
to be effective against various cancer lines, including testicular, ovarian and solid tumours of the head
and neck [266–271]. Its success arises due to its mechanism of action: cisplatin is able to bind DNA and,
as a result, to induce apoptosis. Once inside the cell, cisplatin reacts with DNA at the N7 position of
the major groove guanines, which is the most exposed and nucleophilic site. Mono- and bifunctional
adducts are then formed between cisplatin and DNA as a result of inter- and intra-crosslinks [272,273].
Despite its activity, the use of cisplatin results in serious side effects due to its mechanism
of action. The most relevant side effects are kidney damage and hearing loss. Nephrotoxicity is
related to the accumulation of cisplatin in the kidney proximal tubule [274,275], whereas ototoxicity
arises due to the death of cochlear sensory hair cells resulting from the increase in reactive oxygen
species [274–276]. In addition, an increase in tumour resistance to cisplatin treatment has been observed.
The most widespread resistance mechanism involves an increase in the repair of cisplatin-DNA
adducts. An increase in cytosolic drug inactivation and a reduction in drug uptake are other
possibilities [277,278].
In order to maintain the efficacy of cisplatin without its shortcomings, numerous analogues,
amongst which oxaliplatin and carboplatin stand out, have been developed. Thus, oxaliplatin
is one of the most common drugs used in colorectal cancer chemotherapy. The importance of
oxaliplatin, or trans-L-diaminocyclohexaneoxalatoplatinum, resides in the absence of cross-resistance
with cisplatin, thus allowing it to be used when a tumour shows resistance to this drug. This absence of
Int. J. Mol. Sci. 2017, 18, 197 23 of 39
cross-resistance with cisplatin is due to the different mismatch-repair proteins that recognize each kind
of adduct, and also explains their different side effects [279]. However, what is more remarkable is that
oxaliplatin does not induce ototoxicity and nephrotoxicity. Oxaliplatin is commonly administered in
combination with infusional 5-fluorouracil/leucovorin, a regime called FOLFOX [280]. FOLFOX has
greatly improved the response rate: 5-fluorouracil treatment gives a response rate of 20%, whereas this
increases to 50% when combined with oxaliplatin [281]. The 5-fluorouracil and oxaliplatin combination
also provides a better survival rate in metastatic patients [281,282].
5.6.2. Gold
Many metal-based anticancer drugs containing gold(I) or gold(III) have been designed over
the past few decades. However, the structures of these compounds are quite different as the
gold atom can be coordinated to phosphines, carbine ligands, porphyrinates or dithiocarbamates
in order to improve its antitumour effect and other properties [267,283–286]. One of the best
characterized gold-containing anticancer drug is known as auranofin. [2,3,4,6-Tetra-o-acetyl-1-thio-
β-D-glycopyranosato(triethylphosphine)gold], is a gold(I) compound containing phosphine and thiol
ligands traditionally used as an antirheumatic drug [287]. The mechanism of action of auranofin
involves the inhibition of thioredoxin reductase, which leads to an increase in reactive oxygen species
that causes oxidative stress and finally triggers intrinsic apoptosis [288]. As a result, auranofin is able to
induce apoptosis even in cisplatin-resistant cancer cells [289].
As the gold atom included in auranofin is responsible for thioredoxin reductase inhibition, other
gold-containing drugs are also able to induce apoptosis in cancer cell [290–292]. Gold atoms are
strongly attracted to thiol and selenol groups and can therefore bind selenium-dependent proteins
such as thioredoxin reductase, which is upregulated in some kinds of cancers, such as colorectal cancer,
and is directly implicated in tumour progression and survival [293], meaning that inhibition thereof
triggers cancer cell death [294].
Inhibition of thioredoxin reductase is not the only mechanism that gold-containing drugs can
use against colorectal cancer. Thus, auranofin can inhibit the ubiquitin-proteasome system [288,295],
which is critical for colon cancer cell homeostasis [296]. Once again, this affinity is extensible to all
gold-containing drugs. In particular, gold(I) derivatives disrupt the redox balance, increasing ROS
levels inside the cell and altering the mitochondrial membrane potential, which induces activation of
the apoptosis cascade and results in controlled cell death, rather than affecting nucleic acids [297–303].
6. Discussion and Future Perspectives
Because of its high incidence and mortality rate worldwide, colorectal cancer (CRC) has become
a global public health problem. Herein we have reviewed the latest discoveries in the study of CRC
research, as well as the newest findings in diagnostic and treatment methodologies in order to provide
researchers and clinicians with an updated vision of the key insights into this disease.
The onset and development of CRC is induced by a combination of genetic and environmental
factors, whose study is essential for the establishment of new prevention strategies—one of the
most important lines of action to stop the increase in its incidence. Over the last decade, the major
colon cancer genes have been identified and their pathogenic variants have been associated with a
high susceptibility to CRC. Moreover, the study of their inheritance patterns led to the discovery of
Hereditary Colorectal Cancer Syndromes, which can now be diagnosed, as well as to special risk
management programs and genetic counseling that can be applied to patients and their relatives,
reducing their risk of suffering from this disease. However, familial clustering of colon cancer also
occurs outside of the setting of well-characterized colon cancer family syndromes; therefore, different
epidemiological studies are being carried out with the aim to identify polymorphisms underlying
susceptibility to CRC in different populations. Results obtained in those studies can set the foundation
for a new generation of genetic screening tests.
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Although most of the major cancer genes involved in CRC have been well characterized,
the influence of additional environmental factors in this disease remains undefined. In this context,
a more in-depth study of the relationship between diet, microbiota and CRC is needed. The results of
these studies might lead to the establishment of a set of lifestyle changes that contribute to reducing
the risk of developing CRC. Moreover, since the composition of microbiota also seems to influence
the development of CRC, adjuvant therapies based on probiotics and prebiotics are being studied to
improve the response to traditional chemotherapeutic agents and to reduce dosage and frequency of
drug administration, resulting in an improvement of the patient’s quality of life.
Similarly, the development and implementation of new specific and more sensitive biomarkers
in the foreseeable future will improve diagnostic strategies, thus allowing clinicians to detect CRC
cases in the earliest stages of the disease and hence to improve the prognosis of thousands of patients.
Currently, only the determination of MSI and KRAS mutations in tumour samples are in use with
diagnostic and therapy management purposes. For early diagnosis of CRC, different tests based on
miRNA expression, gene microarrays, and CpG island methylation phenotype are under evaluation
and, although they have a promising future, further studies of larger populations are needed for
their validation.
In the context of treatment, personalized medicine is fast becoming an indispensable tool. Thus,
it is necessary to perform an in-depth analysis of the tumour features of each patient to find the most
appropriate treatment.
Finally, an extensive part of current research into CRC is focused on the development of new
therapies that are less aggressive and more effective than conventional ones. Discoveries in this area
and their clinical implementation will improve the overall survival and quality of life of CRC patients
in the future.
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